These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 38068538)
41. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. Osmancik P; Herman D; Neuzil P; Hala P; Taborsky M; Kala P; Poloczek M; Stasek J; Haman L; Branny M; Chovancik J; Cervinka P; Holy J; Kovarnik T; Zemanek D; Havranek S; Vancura V; Opatrny J; Peichl P; Tousek P; Lekesova V; Jarkovsky J; Novackova M; Benesova K; Widimsky P; Reddy VY; J Am Coll Cardiol; 2020 Jun; 75(25):3122-3135. PubMed ID: 32586585 [TBL] [Abstract][Full Text] [Related]
42. Risk of Stroke vs. Intracerebral Hemorrhage in Patients with Non-Valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Comparing Dual vs. Triple Antithrombotic Therapy. Desai A; Escamilla-Ocanas C; Dilip D; Saber H; Damani R J Stroke Cerebrovasc Dis; 2021 Apr; 30(4):105654. PubMed ID: 33578352 [TBL] [Abstract][Full Text] [Related]
43. Predictive accuracy of CHA2DS2-VASc and HAS-BLED scores in patients without atrial fibrillation undergoing percutaneous coronary intervention and discharged on dual antiplatelet therapy. Capodanno D; Rossini R; Musumeci G; Lettieri C; Senni M; Valsecchi O; Angiolillo DJ; Lip GY Int J Cardiol; 2015 Nov; 199():319-25. PubMed ID: 26241637 [TBL] [Abstract][Full Text] [Related]
44. Safety and efficacy of short-term (1 to 3 months) dual antiplatelet therapy in patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. Kheiri B; Simpson TF; Osman M; Golwala H; Radaideh Q; Kumar K; Rahmouni H; Divanji P; Cigarroa JE; Zahr F J Thromb Thrombolysis; 2020 Nov; 50(4):867-873. PubMed ID: 32607653 [TBL] [Abstract][Full Text] [Related]
45. Comparative Efficacy and Safety of P2Y12 Inhibitor Monotherapy and Dual Antiplatelet Therapy in Patients with and without Diabetes Mellitus Undergoing Percutaneous Coronary Intervention. Feng WH; Chang YC; Lin YH; Chen HL; Chang HM; Chu CS Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35562942 [TBL] [Abstract][Full Text] [Related]
46. Use and Outcomes of Triple Therapy Among Older Patients With Acute Myocardial Infarction and Atrial Fibrillation. Hess CN; Peterson ED; Peng SA; de Lemos JA; Fosbol EL; Thomas L; Bhatt DL; Saucedo JF; Wang TY J Am Coll Cardiol; 2015 Aug; 66(6):616-27. PubMed ID: 26248987 [TBL] [Abstract][Full Text] [Related]
47. Bleeding risks associated with anticoagulant therapies after percutaneous coronary intervention in Japanese patients with ischemic heart disease complicated by atrial fibrillation: A comparative study. Nakamura M; Yamashita T; Hayakawa A; Matsumoto T; Takita A; Hasegawa C; Uchino K; Sekine T; Iizuka T; Tanabe H; Kogure S J Cardiol; 2021 Feb; 77(2):186-194. PubMed ID: 32943280 [TBL] [Abstract][Full Text] [Related]
48. An analysis of antithrombotic therapy in elderly patients with atrial fibrillation undergoing percutaneous coronary interventions. Zhou J; Wang X; Yu J; Wu Y; Li X; Xie X; Zhang X; Cheng D; Yang B Clin Exp Pharmacol Physiol; 2023 Jul; 50(7):583-593. PubMed ID: 37057840 [TBL] [Abstract][Full Text] [Related]
49. Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention During 2-Year Follow-Up, from a Nationwide Population Study. Park J; Choi EK; Han KD; Choi YJ; Lee SR; Cha MJ; Kang J; Park KW; Oh S; Lip GYH Am J Cardiol; 2019 Jun; 123(12):1921-1926. PubMed ID: 30967291 [TBL] [Abstract][Full Text] [Related]
50. Comparison Between Long-Term Clinical Outcomes of Vitamin K Antagonist and Direct Oral Anticoagulants in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. Yoshida R; Morishima I; Takagi K; Morita Y; Tsuboi H; Murohara T Circ J; 2018 Jul; 82(8):2016-2024. PubMed ID: 29863094 [TBL] [Abstract][Full Text] [Related]
51. Comparing the clinical outcomes in patients with atrial fibrillation receiving dual antiplatelet therapy and patients receiving an addition of an anticoagulant after coronary stent implantation: A systematic review and meta-analysis of observational studies. Chaudhary N; Bundhun PK; Yan H Medicine (Baltimore); 2016 Dec; 95(50):e5581. PubMed ID: 27977592 [TBL] [Abstract][Full Text] [Related]
52. An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI). Gibson CM; Mehran R; Bode C; Halperin J; Verheugt F; Wildgoose P; van Eickels M; Lip GY; Cohen M; Husted S; Peterson E; Fox K Am Heart J; 2015 Apr; 169(4):472-8.e5. PubMed ID: 25819853 [TBL] [Abstract][Full Text] [Related]
53. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial. Vranckx P; Lewalter T; Valgimigli M; Tijssen JG; Reimitz PE; Eckardt L; Lanz HJ; Zierhut W; Smolnik R; Goette A Am Heart J; 2018 Feb; 196():105-112. PubMed ID: 29421002 [TBL] [Abstract][Full Text] [Related]
54. Rivaroxaban Monotherapy in Atrial Fibrillation and Stable Coronary Artery Disease Across Body Mass Index Categories. Ishii M; Kaikita K; Yasuda S; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H; Tsujita K; JACC Asia; 2022 Dec; 2(7):882-893. PubMed ID: 36713761 [TBL] [Abstract][Full Text] [Related]
55. Vitamin K antagonists with or without long-term antiplatelet therapy in outpatients with stable coronary artery disease and atrial fibrillation: Association with ischemic and bleeding events. Lemesle G; Ducrocq G; Elbez Y; Van Belle E; Goto S; Cannon CP; Bauters C; Bhatt DL; Steg PG; Clin Cardiol; 2017 Oct; 40(10):932-939. PubMed ID: 28692742 [TBL] [Abstract][Full Text] [Related]
56. Revisiting the effects of omitting aspirin in combined antithrombotic therapies for atrial fibrillation and acute coronary syndromes or percutaneous coronary interventions: meta-analysis of pooled data from the PIONEER AF-PCI, RE-DUAL PCI, and AUGUSTUS trials. Potpara TS; Mujovic N; Proietti M; Dagres N; Hindricks G; Collet JP; Valgimigli M; Heidbuchel H; Lip GYH Europace; 2020 Jan; 22(1):33-46. PubMed ID: 31603196 [TBL] [Abstract][Full Text] [Related]
57. Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Park J; Jung JH; Choi EK; Lee SW; Kwon S; Lee SR; Kang J; Han KD; Park KW; Oh S; Lip GYH PLoS One; 2022; 17(2):e0264538. PubMed ID: 35213632 [TBL] [Abstract][Full Text] [Related]
58. Anticoagulant and Antiplatelet Prescribing Patterns for Patients with Atrial Fibrillation after Percutaneous Coronary Intervention. Woods EA; Ackman ML; Graham MM; Koshman SL; Boswell RM; Barry AR Can J Hosp Pharm; 2016; 69(4):280-5. PubMed ID: 27621487 [TBL] [Abstract][Full Text] [Related]
59. Rivaroxaban Monotherapy in Patients With Atrial Fibrillation After Coronary Stenting: Insights From the AFIRE Trial. Matoba T; Yasuda S; Kaikita K; Akao M; Ako J; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H; JACC Cardiovasc Interv; 2021 Nov; 14(21):2330-2340. PubMed ID: 34736731 [TBL] [Abstract][Full Text] [Related]
60. Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease. Yasuda S; Kaikita K; Akao M; Ako J; Matoba T; Nakamura M; Miyauchi K; Hagiwara N; Kimura K; Hirayama A; Matsui K; Ogawa H; N Engl J Med; 2019 Sep; 381(12):1103-1113. PubMed ID: 31475793 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]